AbbVie states deaths in joint disease trial not associated with drug

AbbVie Corporation stated on Monday two patients died inside a late-stage trial of their rheumatoid arthritis symptoms drug however that the deaths weren’t from the drug, which met the study’s primary goals.

The trial was evaluating two doses from the drug upadacitinib – 15 mg and 30 mg – in patients with moderate to severe rheumatoid arthritis symptoms, who didn’t adequately react to or were intolerant with other anti-rheumatic drugs.

Upadacitinib, a once-daily pill, is associated with a category of medication referred to as JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases and are used to deal with rheumatoid arthritis symptoms among other illnesses.

Rheumatoid arthritis symptoms, a chronic inflammatory disease where the defense mechanisms attacks tissues within the joints, affects greater than 23 million people.

“Following the 2nd positive phase 3 trial … we feel this drug can be the greatest-in-class JAK inhibitor. We remain confident with its safety profile, ” Jefferies analyst Jeffrey Holford authored inside a client note.

If approved, Upadacitinib could reduce AbbVie’s reliance on its flagship rheumatoid arthritis symptoms treatment Humira, which generated greater than $16 billion in sales this past year.

The drugmaker stated the reason behind among the deaths was unknown, as the second patient died because of heart failure and presumed lung embolism, or thrombus within the lung area.

“At time of initial report, both occasions were considered through the investigator as getting no reasonable chance of being associated with the research drug,” AbbVie’s spokeswoman Jillian Griffin told Reuters.

Eli Lilly and Co’s rival rheumatoid arthritis symptoms drug, baricitinib, additionally a JAK inhibitor, hit a roadblock in April once the U.S. Fda declined to approve it, calling for the next clinical study.

Three several weeks later, Lilly stated the Food and drug administration was worried about a little, but elevated quantity of potentially harmful thrombus observed in baricitinib patients in numerous studies, outlining a probable multi-year delay for that drug.

Pfizer Inc’s Xeljanz may be the only approved JAK inhibitor within the U . s . States to deal with rheumatoid arthritis symptoms.

AbbVie’s shares were marginally lower in morning buying and selling on Monday.